Biotech Values

[isolution]

Squalamine may not be effective as intravitreal injection

Thanks Winchem for reminding this excellent study. If that is true, they could have a problem for their only choice would be systemic delivery in phase III and you know that long-term side-effect appear in PhIII.
Also, I think FDA will never allow systemic delivery to treat eye diseases (except for diabetic retinopathy that also concerns the rest of the body).
Still we don't known the Squalamine MOA. In the article, they explain that Squalamine may improve retinal oxygenation and then suppress hypoxia mediated signaling for VEGF. In summary, it looks like an anti-VEGF drug but it is not.
If that is the true MOA, then it will have to be delivered systematically to work.